Results 11 to 20 of about 23,157 (220)

Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

EClinicalMedicine, 2021
Background: Tenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp). Several cohorts reported that people treated by tenofovir disoproxil fumarate and emtricitabine are less likely to develop SARS ...
Jean-Jacques Parienti, Thierry Prazuck, Laure Peyro-Saint-Paul, Anna Fournier, Cécile Valentin, Sylvie Brucato, Renaud Verdon, Aymeric Sève, Mathilda Colin, Fabien Lesne, Jérome Guinard, Meriadeg Ar Gouilh, Julia Dina, Astrid Vabret, Laurent Hocqueloux   +14 more
doaj   +2 more sources

Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care [PDF]

Infectious Diseases and Therapy
Introduction Adherence to antiretroviral therapy (ART) is crucial for people with HIV (PWH) to maintain health. The Medicare program insures a substantial proportion of PWH in the United States; however, few studies have evaluated ART treatment patterns ...
Suying Li, Uche Mordi, Mary J. Christoph, Haifeng Guo, David T. Gilbertson, Tianye Cui, Travis Lim, Neia Prata Menezes, Woodie Zachry, Phyllis C. Tien   +9 more
doaj   +2 more sources

Emtricitabine

Drugs, 2003
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada, Terri Levien, Danial E. Baker   +2 more
  +8 more sources

Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials

EClinicalMedicine, 2023
Summary Background Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen recommended for HIV-1 treatment. The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegravir ...
P. Sax, J. Arribas, C. Orkin, A. Lazzarin, A. Pozniak, E. Dejesus, F. Maggiolo, H. Stellbrink, Y. Yazdanpanah, Rima K. Acosta, Hailin Huang, J. Hindman, Hal Martin, J. Baeten, D. Wohl   +14 more
semanticscholar   +1 more source

Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts

HIV Medicine, 2023
Real‐world evidence is an essential component of evidence‐based medicine. The aim of the BICSTaR (BICtegravir Single Tablet Regimen) study is to assess effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ...
Stefan Esser, J. Brunetta, A. Inciarte, Itzchak Levy, Antonella d’Arminio Monforte, John S. Lambert, B. V. van Welzen, Katsuji Teruya, M. Boffito, Chun-Eng Liu, Ozlem Altuntas Aydin, D. Thorpe, Marion Heinzkill, A. Marongiu, Tali Cassidy, R. Haubrich, Lisa D'Amato, Olivier Robineau   +17 more
semanticscholar   +1 more source

A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV

AIDS (London), 2023
Objective: The objective of this study was to assess the pharmacokinetics, safety, and efficacy and confirm the dose of once-daily bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF; B/F/TAF) during pregnancy. Design: An open-label, multicenter,
Haeyoung Zhang, J. Hindman, Ludwig Lin, M. Davis, Justin Shang, Deqing Xiao, A. Avihingsanon, Priyanka Arora, R. Palaparthy, Sandhya Girish, Dhananjay D. Marathe   +10 more
semanticscholar   +1 more source

Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium

HIV Medicine, 2023
Our objective was to evaluate the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a real‐world setting in Belgium.
R. Nasreddine, E. Florence, J. Yombi, S. Henrard, G. Darcis, J. V. Van Praet, L. Vandekerckhove, Sabine D Allard, R. Demeester, P. Messiaen, N. Ausselet, M. Delforge, S. De Wit   +12 more
semanticscholar   +1 more source

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir

PLoS ONE, 2023
Introduction Integrase strand transfer inhibitors (INSTI) are one of the most prescribed drug classes for the treatment of HIV infection worldwide. Emtricitabine/Tenofovir Alafenamide/ Bictegravir (FTC/TAF/BIC) has been evaluated in randomized clinical ...
N. Squillace, E. Ricci, P. Maggi, L. Taramasso, B. Menzaghi, G. D. De Socio, S. Piconi, Benedetto Maurizio Celesia, G. Orofino, E. Sarchi, G. Pellicanò, Filomena Simeone, L. Valsecchi, A. Bandera, G. Cenderello, L. Attala, G. Angioni, K. Falasca, A. Cascio, O. Bargiacchi, A. di Biagio, P. Bonfanti   +21 more
semanticscholar   +1 more source

Solubility Data, Solubility Parameters and Thermodynamic Behavior of an Antiviral Drug Emtricitabine in Different Pure Solvents: Molecular Understanding of Solubility and Dissolution

Molecules, 2021
The solubility values, various Hansen solubility parameters (HSPs) and thermodynamic behavior of emtricitabine (ECT) in twelve different pure solvents (PS) were estimated using various experimental as well as computational methods.
Faiyaz Shakeel, Nazrul Haq, Ibrahim Alsarra, Sultan Alshehri   +3 more
doaj   +1 more source

Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.

Clinical Infectious Diseases, 2022
Participants randomised to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC+DTG or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks ...
Bronwyn Bosch, Godspower Akpomiemie, N. Chandiwana, S. Sokhela, Andrew Hill, K. McCann, A. Qavi, Manya Mirchandani, W. Venter   +8 more
semanticscholar   +1 more source